A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. (2016)
Attributed to:
Establishment of the Cambridge Single Cell Analysis Clinical Core Facility [SCACCF]
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1126/scitranslmed.aad3744
PubMed Identifier: 27252175
Publication URI: http://europepmc.org/abstract/MED/27252175
Type: Journal Article/Review
Volume: 8
Parent Publication: Science translational medicine
Issue: 341
ISSN: 1946-6234